Business Context and Reporting Period
Company: Scinai Immunotherapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: August 2026 (Announcement Date: August 19, 2026)
The Company announced a change to its American Depositary Share (ADS) ratio effective August 21, 2026. This action is intended to increase the per-ADS trading price and regain compliance with Nasdaq Listing Rule 5550(a)(2), which mandates a minimum bid price of $1.00 per ADS.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure adjustments regarding the ADS ratio.
Material Changes
- ADS Ratio Change: The ratio of ADSs to ordinary shares will change from 1 ADS representing 4,000 ordinary shares to 1 ADS representing 40,000 ordinary shares.
- Effective Date: August 21, 2026.
- Trading Impact: ADSs will begin trading on an adjusted basis on the Nasdaq Capital Market under the symbol "SCNI" with a new CUSIP number (09073Q402).
- Equivalent Action: The change has the same effect as a one-for-ten reverse split of the ADSs.
Outlook, Risks, and Management Commentary
- Objective: To increase the per-ADS trading price and maintain Nasdaq listing compliance.
- Fractional Shares: No fractional new ADSs will be issued. Fractional entitlements will be aggregated, and the depositary bank will attempt to sell them, distributing net cash proceeds to applicable holders.
- Risk Warning: The Company states there can be no assurance that the ADS Ratio Change will enable it to regain or maintain compliance with Nasdaq's continued-listing requirements.
- Investor Action: No action is required by ADS holders to effect the change.
Key Facts for Investor Verification
- Verify the new CUSIP number (09073Q402) for future trading.
- Confirm the adjusted trading price on August 21, 2026, to assess if the $1.00 minimum bid price threshold is met.
- Monitor subsequent filings for confirmation of continued Nasdaq listing status.
- Review the depositary bank's handling of fractional share sales and cash distributions.